Unichem Laboratories Limited announced its unaudited financial results for the third quarter and nine months ended December 31, 2025, following a Board Meeting held on February 5, 2026. The company reported a consolidated revenue of ₹5,192.1 million for Q3 FY26, representing a marginal decrease of 2.67% from the previous quarter’s (Q2 FY26) revenue of ₹5,334.2 million. On a year-over-year basis, revenue grew by 14.48% compared to ₹4,535.1 million in Q3 FY25. The company’s bottom line was significantly impacted by an exceptional item of ₹2,750 million related to the impairment of goodwill of its US subsidiary, leading to a net loss of ₹2,581.4 million for the quarter. This is a sharp decline from the net profit of ₹104.7 million in the previous quarter and ₹182.2 million in the corresponding quarter of the previous year.

Established in 1962, Unichem Laboratories Limited is a veteran in the Indian pharmaceutical industry, primarily focused on the development, manufacturing, and marketing of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The company operates several manufacturing facilities across India, including plants in Ghaziabad, Goa, and Kolhapur, with a strong emphasis on regulated markets like the US and Europe. In recent 2025 updates, Unichem entered the entertainment sector by acquiring a 51% stake in Hi-end for ₩6.1 billion and integrated its US formulations business under a single entity to streamline operations. As of 2025, Ipca Laboratories Limited remains the company’s most significant institutional investor, holding a controlling stake of approximately 52.67%.